| Year |
Citation |
Score |
| 2021 |
Danila MI, Allison JJ, Goins KV, Chiriboga G, Fischer M, Puliafico M, Mudano AS, Rahn EJ, Merchant J, Lawrence CE, Dunkel L, Israel T, Barton B, Jenoure F, Alexander T, et al. Development of a multi-component intervention to promote participation of Black and Latinx individuals in biomedical research. Journal of Clinical and Translational Science. 5: e134. PMID 34367678 DOI: 10.1017/cts.2021.797 |
0.395 |
|
| 2020 |
Lawrence CE, Dunkel L, McEver M, Israel T, Taylor R, Chiriboga G, Goins KV, Rahn EJ, Mudano AS, Roberson ED, Chambless C, Wadley VG, Danila MI, Fischer MA, Joosten Y, et al. A REDCap-based model for electronic consent (eConsent): Moving toward a more personalized consent. Journal of Clinical and Translational Science. 4: 345-353. PMID 33244416 DOI: 10.1017/cts.2020.30 |
0.404 |
|
| 2016 |
Kennedy AJ, Rahn EJ, Paulukaitis BS, Savell KE, Kordasiewicz HB, Wang J, Lewis JW, Posey J, Strange SK, Guzman-Karlsson MC, Phillips SE, Decker K, Motley ST, Swayze EE, Ecker DJ, et al. Tcf4 Regulates Synaptic Plasticity, DNA Methylation, and Memory Function. Cell Reports. PMID 27568567 DOI: 10.1016/J.Celrep.2016.08.004 |
0.58 |
|
| 2014 |
Rahn EJ, Deng L, Thakur GA, Vemuri K, Zvonok AM, Lai YY, Makriyannis A, Hohmann AG. Prophylactic cannabinoid administration blocks the development of paclitaxel-induced neuropathic nociception during analgesic treatment and following cessation of drug delivery. Molecular Pain. 10: 27. PMID 24742127 DOI: 10.1186/1744-8069-10-27 |
0.599 |
|
| 2011 |
Rahn EJ, Thakur GA, Wood JA, Zvonok AM, Makriyannis A, Hohmann AG. Pharmacological characterization of AM1710, a putative cannabinoid CB2 agonist from the cannabilactone class: antinociception without central nervous system side-effects. Pharmacology, Biochemistry, and Behavior. 98: 493-502. PMID 21382397 DOI: 10.1016/J.Pbb.2011.02.024 |
0.579 |
|
| 2010 |
Rahn EJ, Zvonok AM, Makriyannis A, Hohmann AG. Antinociceptive effects of racemic AM1241 and its chirally synthesized enantiomers: lack of dependence upon opioid receptor activation. The Aaps Journal. 12: 147-57. PMID 20127295 DOI: 10.1208/S12248-009-9170-8 |
0.577 |
|
| 2009 |
Rahn EJ, Hohmann AG. Cannabinoids as pharmacotherapies for neuropathic pain: from the bench to the bedside. Neurotherapeutics : the Journal of the American Society For Experimental Neurotherapeutics. 6: 713-37. PMID 19789075 DOI: 10.1016/J.Nurt.2009.08.002 |
0.564 |
|
| 2008 |
Rahn EJ, Zvonok AM, Thakur GA, Khanolkar AD, Makriyannis A, Hohmann AG. Selective activation of cannabinoid CB2 receptors suppresses neuropathic nociception induced by treatment with the chemotherapeutic agent paclitaxel in rats. The Journal of Pharmacology and Experimental Therapeutics. 327: 584-91. PMID 18664590 DOI: 10.1124/Jpet.108.141994 |
0.634 |
|
| 2007 |
Rahn EJ, Makriyannis A, Hohmann AG. Activation of cannabinoid CB1 and CB2 receptors suppresses neuropathic nociception evoked by the chemotherapeutic agent vincristine in rats. British Journal of Pharmacology. 152: 765-77. PMID 17572696 DOI: 10.1038/Sj.Bjp.0707333 |
0.627 |
|
| 2007 |
Rahn E, Hohmann A. 289 CANNABINOIDS SUPPRESS CHEMOTHERAPY-EVOKED PAINFUL PERIPHERAL NEUROPATHY THROUGH SPINAL SITES OF ACTION European Journal of Pain. 11: S128-S128. DOI: 10.1016/J.Ejpain.2007.03.304 |
0.565 |
|
| 2007 |
Hohmann A, Rahn E, Maxwell K, Zvonok A, Makriyannis A. 276 SELECTIVE ACTIVATION OF CANNABINOID CB2 RECEPTORS SUPPRESSES CHEMOTHERAPEUTIC NEUROPATHY EVOKED BY PACLITAXEL AND VINCRISTINE ADMINISTRATION European Journal of Pain. 11: S122-S122. DOI: 10.1016/J.Ejpain.2007.03.291 |
0.587 |
|
| Show low-probability matches. |